Compare
Dyne Therapeutics, Inc. vs Arcus Biosciences, Inc. vs Madrigal Pharmaceuticals, Inc. vs Pacira BioSciences, Inc.
| Latest fiscal year | Dyne Therapeutics, Inc. DYN | Arcus Biosciences, Inc. RCUS | Madrigal Pharmaceuticals, Inc. MDGL | Pacira BioSciences, Inc. PCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $247.00M | $958.40M | $726.41M |
| Revenue growth (YoY) | n/a | -4.3% | +432.1% | +3.6% |
| Gross margin | n/a | n/a | n/a | 79.4% (computed) |
| Operating margin | n/a | -156.3% | -31.3% | 2.6% |
| Net margin | n/a | -142.9% | -30.1% | 1.0% |
| Net income | -$446.21M | -$353.00M | -$288.28M | $7.03M |
| EPS (Diluted) | -$3.47 | -$3.29 | -$12.85 | $0.16 |
| Operating cash flow | -$403.21M | -$482.00M | -$189.55M | $151.99M |
| Free cash flow | -$405.13M | -$484.00M | -$190.02M | $136.66M |
| Cash & equivalents | $893.37M | $222.00M | $198.69M | $158.54M |
| Total assets | $1.19B | $1.14B | $1.26B | $1.26B |
| Total liabilities | $214.83M | n/a | $656.90M | $571.81M |
| Shareholders' equity | $972.13M | $631.00M | $602.69M | $693.11M |
| Return on year-end equity | -45.9% | -55.9% | -47.8% | 1.0% |
| Shares outstanding | 164.95M | 125.30M | 22.84M | 41.12M |
Revenue, most recent five fiscal years
| Fiscal year | Dyne Therapeutics, Inc. | Arcus Biosciences, Inc. | Madrigal Pharmaceuticals, Inc. | Pacira BioSciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $247.00M Ended 2025-12-31 | $958.40M Ended 2025-12-31 | $726.41M Ended 2025-12-31 |
| 1 year earlier | n/a | $258.00M Ended 2024-12-31 | $180.13M Ended 2024-12-31 | $700.97M Ended 2024-12-31 |
| 2 years earlier | n/a | $117.00M Ended 2023-12-31 | $0 Ended 2023-12-31 | $674.98M Ended 2023-12-31 |
| 3 years earlier | n/a | $112.00M Ended 2022-12-31 | $0 Ended 2022-12-31 | $666.82M Ended 2022-12-31 |
| 4 years earlier | n/a | $383.00M Ended 2021-12-31 | $0 Ended 2021-12-31 | $541.53M Ended 2021-12-31 |